Olaparib monotherapy in patients with advanced relapsed ovarian cancer and a germline BRCA1/2 mutation: a multistudy analysis of response rates and safety

The PARP inhibitor olaparib (Lynparza™) demonstrates antitumor activity in women with relapsed ovarian cancer and a germline BRCA1/2 mutation (gBRCAm). Data from olaparib monotherapy trials were used to explore the treatment effect of olaparib in patients with gBRCAm ovarian cancer who had received...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Annals of oncology 2016-06, Vol.27 (6), p.1013-1019
Hauptverfasser:	Matulonis, U.A., Penson, R.T., Domchek, S.M., Kaufman, B., Shapira-Frommer, R., Audeh, M.W., Kaye, S., Molife, L.R., Gelmon, K.A., Robertson, J.D., Mann, H., Ho, T.W., Coleman, R.L.
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Aged BRCA1 Protein - genetics BRCA1/2 mutation BRCA2 Protein - genetics Clinical Trials as Topic Disease-Free Survival Female Germ-Line Mutation Humans Middle Aged monotherapy Neoplasm Recurrence, Local - pathology olaparib ovarian cancer Ovarian Neoplasms - drug therapy Ovarian Neoplasms - genetics Ovarian Neoplasms - pathology Phthalazines - administration & dosage Phthalazines - adverse effects Piperazines - administration & dosage Piperazines - adverse effects Poly(ADP-ribose) Polymerase Inhibitors - administration & dosage Poly(ADP-ribose) Polymerase Inhibitors - adverse effects pooled analysis
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!